Oleg N. Minushkin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Oleg N. Minushkin has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Leonid V. Maslovskii
Central State Medical Academy of Department for Presidential Affairs of the Russian Federation
12 shared publications - Igor V. Zverkov
Central State Medical Academy of the Administrative Department of the President of the Russian Federation
9 shared publications - Maria D. Ardatskaya
Central State Medical Academy
5 shared publications - Tatiana Topchiy
Central State Medical Academy of the President of the Russian Federation
5 shared publications - Tat'Jana L. Pilat
Research Institute of Occupational Medicine named after Academician N.F. Izmerov
4 shared publications - V. S. Inevatova
Aidiklinik LLC
4 shared publications
Latest Publications
- Open Access
- 24 October 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 15,p. 53-63
Comparative efficacy of multi-enzyme products in patients with exocrine pancreatic insufficiency
Introduction. Chronic relapsing pancreatitis or pancreatic resection eventually results in exocrine pancreatic insufficiency, leading to impaired digestion, and metabolic and electrolyte disturbances. Patients with such disorders develop a severe symptom complex associated with increased mortality, which requires early diagnosis and appropriate treatment. Aim. To compare the efficacy and safety of Digestium Forte (pancreatin + hemicellulase) supplement and Ermital in patients with exocrine pancreatic insufficiency based on clinical, instrumental, and laboratory parameters. Materials and methods . We conducted a comparative study using Ermital as a comparator. A total of 101 patients with chronic pancreatitis and exocrine pancreatic insufficiency confirmed by the elastase test results were included in the study. The first group (treatment group) consisted of 52 patients treated with Digestium Forte (pancreatin + hemicellulase) supplement. The second group (comparator group) consisted of 49 patients treated with Ermital. Therapy efficacy was assessed based on clinical data (changes in symptoms and patients’ quality of life using the GSRS questionnaire) and laboratory/instrumental findings (changes in coprogram results, severity of malnutrition, bowel transit time using the carbolene test, and ultrasound examination). Results. The study revealed that adding hemicellulase to pancreatin resulted in a significant reduction in bloating, feeling of fullness, and borborygmi, as well as improved quality of life in patients with exocrine pancreatic insufficiency, starting from week 2 or 3 of treatment. Both products demonstrated comparable efficacy in terms of impact on nutritional status, coprogram parameters, pancreatic transabdominal ultrasound findings, and intestinal transit time (the carbolene test results). Conclusions. The findings derived from study data gave reasons to consider treatment with Digestium Forte (pancreatin + hemicellulase) supplement as a priority approach for patients with exocrine pancreatic insufficiency.
- 24 October 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 15,p. 53-63
Open AccessComparative efficacy of multi-enzyme products in patients with exocrine pancreatic insufficiency
Introduction. Chronic relapsing pancreatitis or pancreatic resection eventually results in exocrine pancreatic insufficiency, leading to impaired digestion, and metabolic and electrolyte disturbances. Patients with such disorders develop a severe symptom complex associated with increased mortality, which requires early diagnosis and appropriate treatment. Aim. To compare the efficacy and safety of Digestium Forte (pancreatin + hemicellulase) supplement and Ermital in patients with exocrine pancreatic insufficiency based on clinical, instrumental, and laboratory parameters. Materials and methods . We conducted a comparative study using Ermital as a comparator. A total of 101 patients with chronic pancreatitis and exocrine pancreatic insufficiency confirmed by the elastase test results were included in the study. The first group (treatment group) consisted of 52 patients treated with Digestium Forte (pancreatin + hemicellulase) supplement. The second group (comparator group) consisted of 49 patients treated with Ermital. Therapy efficacy was assessed based on clinical data (changes in symptoms and patients’ quality of life using the GSRS questionnaire) and laboratory/instrumental findings (changes in coprogram results, severity of malnutrition, bowel transit time using the carbolene test, and ultrasound examination). Results. The study revealed that adding hemicellulase to pancreatin resulted in a significant reduction in bloating, feeling of fullness, and borborygmi, as well as improved quality of life in patients with exocrine pancreatic insufficiency, starting from week 2 or 3 of treatment. Both products demonstrated comparable efficacy in terms of impact on nutritional status, coprogram parameters, pancreatic transabdominal ultrasound findings, and intestinal transit time (the carbolene test results). Conclusions. The findings derived from study data gave reasons to consider treatment with Digestium Forte (pancreatin + hemicellulase) supplement as a priority approach for patients with exocrine pancreatic insufficiency.
- Open Access
- 9 September 2026
- Published by Consilium Medicum in Consilium Medicum
- Vol. 28 (8) , 662-669
Rome Criteria for irritable bowel syndrome, fifth revision: Key updates. A review
The Rome V Criteria, published in 2026, updates the scientific and clinical understanding of irritable bowel syndrome (IBS). It redefines IBS from a “functional disorder” to a “gut-brain interaction disorder,” emphasizing biological underpinnings. Recognized pathophysiological mechanisms include impaired motility, alterations in the microbiota and its metabolites, immune dysregulation, serotonin modulation, increased intestinal permeability, visceral hypersensitivity, and bile acid malabsorption. The updated criteria define IBS as recurrent abdominal pain and/or discomfort associated with changes in bowel habits, such as constipation, diarrhea, or a mixed pattern, with symptoms present for at least six months prior to diagnosis and persisting during the preceding three months. Notable updates include the reintroduction of “abdominal discomfort,” a reduced pain frequency threshold of at least three days per week, clarification that pain or discomfort should not be constant, and an auxiliary criterion specifying that pain or discomfort should not be exclusively related to menstruation. IBS is now classified into four primary subtypes based on predominant stool patterns, as determined by the Bristol Stool Form Scale: IBS with constipation, IBS with diarrhea, IBS with mixed bowel habits, and IBS with unclassified bowel habits. Diagnosis is based on typical symptoms in the absence of alarm features, and IBS is no longer considered a diagnosis of exclusion. The revised diagnostic algorithm involves sequential clinical assessment, targeted use of a limited set of laboratory and instrumental tests, and explicit criteria for further evaluation. The Rome V Criteria also recommend a stepwise approach to IBS therapy, including lifestyle and dietary modifications, pharmacological management of predominant symptoms, and behavioral interventions targeting brain-gut axis interactions.
- 9 September 2026
- Published by Consilium Medicum in Consilium Medicum
- Vol. 28 (8) , 662-669
Open AccessRome Criteria for irritable bowel syndrome, fifth revision: Key updates. A review
The Rome V Criteria, published in 2026, updates the scientific and clinical understanding of irritable bowel syndrome (IBS). It redefines IBS from a “functional disorder” to a “gut-brain interaction disorder,” emphasizing biological underpinnings. Recognized pathophysiological mechanisms include impaired motility, alterations in the microbiota and its metabolites, immune dysregulation, serotonin modulation, increased intestinal permeability, visceral hypersensitivity, and bile acid malabsorption. The updated criteria define IBS as recurrent abdominal pain and/or discomfort associated with changes in bowel habits, such as constipation, diarrhea, or a mixed pattern, with symptoms present for at least six months prior to diagnosis and persisting during the preceding three months. Notable updates include the reintroduction of “abdominal discomfort,” a reduced pain frequency threshold of at least three days per week, clarification that pain or discomfort should not be constant, and an auxiliary criterion specifying that pain or discomfort should not be exclusively related to menstruation. IBS is now classified into four primary subtypes based on predominant stool patterns, as determined by the Bristol Stool Form Scale: IBS with constipation, IBS with diarrhea, IBS with mixed bowel habits, and IBS with unclassified bowel habits. Diagnosis is based on typical symptoms in the absence of alarm features, and IBS is no longer considered a diagnosis of exclusion. The revised diagnostic algorithm involves sequential clinical assessment, targeted use of a limited set of laboratory and instrumental tests, and explicit criteria for further evaluation. The Rome V Criteria also recommend a stepwise approach to IBS therapy, including lifestyle and dietary modifications, pharmacological management of predominant symptoms, and behavioral interventions targeting brain-gut axis interactions.
- Open Access
- 26 February 2026
- Published by LLC Global Media Technology in Experimental and Clinical Gastroenterology
- No. 12,p. 199-218
The Evolution of the gut dysbiosis theory
Ince the discovery of microorganisms, the question of the role and mechanisms of the effect of microflora on the human body has constantly arisen. Views on the microbiota varied depending on the level of its scientific knowledge. The article examines the historical formation and current state of the gut dysbiosis theory. Aim of investigation. To trace the evolution of the gut dysbiosis theory, to summarize modern ideas about the composition, functions and role of the microbiota in maintaining human health, as well as to analyze methods for the diagnosis and correction of microbial balance disorders. Materials and methods. An analytical review of domestic and foreign literature sources on the problem of microbiocenosis has been conducted, including historical data, the results of fundamental and clinical research, as well as a comparative analysis of modern methods for diagnosing gut microbial ecology disorders, including molecular genetic and metabolomic approaches. Results. It has been established that the development of the gut dysbiosis theory has passed through several stages - from the heuristic to the analytical, reflecting the deepening of knowledge about the symbiotic interactions of humans and the microbiota. The main functions of the microbiota (energy supply, immunomodulation, vitamin synthesis, protection against pathogens) have been determined. Classifications and criteria of dysbiosis are presented, modern diagnostic methods are proposed, including gas-liquid chromatography of short-chain fatty acids, which is highly informative. The principles of correction of microbiocenosis disorders using probiotics, prebiotics, synbiotics and metabiotics are substantiated, and the effectiveness of individualized treatment regimens is shown. Conclusion. The modern gut dysbiosis theory is based on the understanding of the microbiota as a full-fledged “metabolic organ”, closely integrated with the macroorganism. The development of molecular and metabolic technologies opens up prospects for personalized medicine, early diagnosis and targeted correction of microecological disorders. Further research should be aimed at studying the mechanisms of interaction of the microbiota with various body systems and developing targeted therapeutic strategies.
- 26 February 2026
- Published by LLC Global Media Technology in Experimental and Clinical Gastroenterology
- No. 12,p. 199-218
Open AccessThe Evolution of the gut dysbiosis theory
Ince the discovery of microorganisms, the question of the role and mechanisms of the effect of microflora on the human body has constantly arisen. Views on the microbiota varied depending on the level of its scientific knowledge. The article examines the historical formation and current state of the gut dysbiosis theory. Aim of investigation. To trace the evolution of the gut dysbiosis theory, to summarize modern ideas about the composition, functions and role of the microbiota in maintaining human health, as well as to analyze methods for the diagnosis and correction of microbial balance disorders. Materials and methods. An analytical review of domestic and foreign literature sources on the problem of microbiocenosis has been conducted, including historical data, the results of fundamental and clinical research, as well as a comparative analysis of modern methods for diagnosing gut microbial ecology disorders, including molecular genetic and metabolomic approaches. Results. It has been established that the development of the gut dysbiosis theory has passed through several stages - from the heuristic to the analytical, reflecting the deepening of knowledge about the symbiotic interactions of humans and the microbiota. The main functions of the microbiota (energy supply, immunomodulation, vitamin synthesis, protection against pathogens) have been determined. Classifications and criteria of dysbiosis are presented, modern diagnostic methods are proposed, including gas-liquid chromatography of short-chain fatty acids, which is highly informative. The principles of correction of microbiocenosis disorders using probiotics, prebiotics, synbiotics and metabiotics are substantiated, and the effectiveness of individualized treatment regimens is shown. Conclusion. The modern gut dysbiosis theory is based on the understanding of the microbiota as a full-fledged “metabolic organ”, closely integrated with the macroorganism. The development of molecular and metabolic technologies opens up prospects for personalized medicine, early diagnosis and targeted correction of microecological disorders. Further research should be aimed at studying the mechanisms of interaction of the microbiota with various body systems and developing targeted therapeutic strategies.
- 27 January 2026
- Published by Alfmed LLC in Medical alphabet
- Vol. 1 (34)
The interrelationship between the exocrine and endocrine functions of the pancreas in health and disease
This article examines the theoretical aspects of the interaction between the exocrine and endocrine parts of the pancreas (P), as well as various pathologies illustrating these processes. The diseases covered include chronic pancreatitis (CP), acute pancreatitis (AP), diabetes mellitus (DM), pancreatic steatosis, and several others. Data on the prevalence of DM in various pancreatic pathologies and the incidence of exocrine pancreatic insufficiency (EPI) in DM are provided. Risk factors for DM in pancreatic pathology are presented. The mechanisms of pathogenesis of these conditions are discussed, and the presented concepts are supported by experimental data. Additionally, several potential therapeutic interventions that may improve treatment efficacy in these conditions are discussed.
- 27 January 2026
- Published by Alfmed LLC in Medical alphabet
- Vol. 1 (34)
The interrelationship between the exocrine and endocrine functions of the pancreas in health and disease
This article examines the theoretical aspects of the interaction between the exocrine and endocrine parts of the pancreas (P), as well as various pathologies illustrating these processes. The diseases covered include chronic pancreatitis (CP), acute pancreatitis (AP), diabetes mellitus (DM), pancreatic steatosis, and several others. Data on the prevalence of DM in various pancreatic pathologies and the incidence of exocrine pancreatic insufficiency (EPI) in DM are provided. Risk factors for DM in pancreatic pathology are presented. The mechanisms of pathogenesis of these conditions are discussed, and the presented concepts are supported by experimental data. Additionally, several potential therapeutic interventions that may improve treatment efficacy in these conditions are discussed.
- 22 January 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 23,p. 64-73
Effectiveness of synbiotic biocomplexes in correction of gut microbiocenosis disorders
The state of the gut microbiota largely determines the course of pathological processes in the human body. Currently, there is no doubt about the role of dysbiosis in the development and progression of many disorders, including intestinal infections, IBS, IBD, SIBO, diverticular disease, celiac disease, cancer, food intolerance, allergies, liver and pancreatic diseases, obesity, diabetes, metabolic syndrome, hematological, cardiological, genitourinary, rheumatological, neurological and neuropsychiatric. The development of tools that correct the imbalance of the gut microbiota is one of the most promising areas of the modern science. Methods for diagnosing disorders of the gut microbiota are also being improved. The importance and expediency of including agents that modulate the state of the gut microbiota in the complex therapy of many diseases is confirmed by numerous foreign and domestic studies. The evolution of probiotic products has progressed from single-strain formulations containing one type of microorganism to modern multi-strain synbiotic complexes that combine probiotics and prebiotics. The first generations of probiotics were primarily aimed at replenishing beneficial bacteria, whereas contemporary biocomplexes exert multi-level effects – they regulate the composition and activity of the gut microbiocenosis, promote the synthesis of necessary bacterial metabolites, improve intestinal barrier function, and modulate the immune response. This review article is devoted to evaluating the effectiveness of synbiotic biocomplexes Normoflorin L, B, and Д in the correction of gut microbiocenosis disorders in antibacterial therapy, functional bowel diseases, inflammatory bowel diseases, chronic pancreatitis, celiac disease, metabolic disorders and obesity, diseases of the ENT organs, dermatological and gynecological diseases.
- 22 January 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 23,p. 64-73
Effectiveness of synbiotic biocomplexes in correction of gut microbiocenosis disorders
The state of the gut microbiota largely determines the course of pathological processes in the human body. Currently, there is no doubt about the role of dysbiosis in the development and progression of many disorders, including intestinal infections, IBS, IBD, SIBO, diverticular disease, celiac disease, cancer, food intolerance, allergies, liver and pancreatic diseases, obesity, diabetes, metabolic syndrome, hematological, cardiological, genitourinary, rheumatological, neurological and neuropsychiatric. The development of tools that correct the imbalance of the gut microbiota is one of the most promising areas of the modern science. Methods for diagnosing disorders of the gut microbiota are also being improved. The importance and expediency of including agents that modulate the state of the gut microbiota in the complex therapy of many diseases is confirmed by numerous foreign and domestic studies. The evolution of probiotic products has progressed from single-strain formulations containing one type of microorganism to modern multi-strain synbiotic complexes that combine probiotics and prebiotics. The first generations of probiotics were primarily aimed at replenishing beneficial bacteria, whereas contemporary biocomplexes exert multi-level effects – they regulate the composition and activity of the gut microbiocenosis, promote the synthesis of necessary bacterial metabolites, improve intestinal barrier function, and modulate the immune response. This review article is devoted to evaluating the effectiveness of synbiotic biocomplexes Normoflorin L, B, and Д in the correction of gut microbiocenosis disorders in antibacterial therapy, functional bowel diseases, inflammatory bowel diseases, chronic pancreatitis, celiac disease, metabolic disorders and obesity, diseases of the ENT organs, dermatological and gynecological diseases.
- Open Access
- 30 December 2025
- Published by Consilium Medicum in Consilium Medicum
- Vol. 27 (12) , 754-761
Combination of non-alcoholic fatty liver disease and cholelithiasis: Pathophysiological and clinical relationships and specific features of therapy. A review
Non-alcoholic fatty liver disease (NAFLD) and cholelithiasis (CL) are widespread diseases worldwide. The combination of NAFLD and CL is a common clinical situation. CL and NAFLD have common risk factors and are closely associated with such concomitant diseases as obesity, dyslipidemia, and carbohydrate metabolism disorders. Numerous studies in different populations have shown that NAFLD is an independent risk factor for CL, and CL is an independent risk factor for NAFLD. Insulin resistance is now being considered as a key link between NAFLD and the development of cholesterol cholelithiasis. In addition, changes in the expression of transcription factors, including hepatic X-receptor, farnesoid X-receptor, and membrane bile acid receptors, play an important role. It leads to increased lipogenesis in the liver and to bile cholesterol supersaturation, contributing to the development of gallstones and fatty liver. An equally important role in the pathogenesis of both diseases is played by gallbladder dysfunction, which serves as an important link between the liver and the intestine within the hepatic-gallbladder-intestinal axis and supports the metabolic homeostasis of cholesterol, triglycerides, and bile acids. It is supported by evidence that cholecystectomy increases the risk of NAFLD, contributes to insulin resistance, and promotes fat accumulation in the liver. The choice of drug therapy in patients with a combination of NAFLD and CL is based on knowledge of the general pathophysiological processes typical of both diseases. Drugs should comply with the principles of multipurpose monotherapy, targeting as many therapeutic targets as possible, and their combination should potentiate each other’s pharmacological effects. The treatment of patients with a combination of NAFLD and CL is primarily based on weight loss through exercise and a Mediterranean diet, enhanced by psyllium-containing agents and butyric acid, a key mediator of the Mediterranean diet’s positive effects. The drug of choice in patients with a combination of NAFLD and CL is ursodeoxycholic acid, exerting a pathogenetic effect on both diseases.
- 30 December 2025
- Published by Consilium Medicum in Consilium Medicum
- Vol. 27 (12) , 754-761
Open AccessCombination of non-alcoholic fatty liver disease and cholelithiasis: Pathophysiological and clinical relationships and specific features of therapy. A review
Non-alcoholic fatty liver disease (NAFLD) and cholelithiasis (CL) are widespread diseases worldwide. The combination of NAFLD and CL is a common clinical situation. CL and NAFLD have common risk factors and are closely associated with such concomitant diseases as obesity, dyslipidemia, and carbohydrate metabolism disorders. Numerous studies in different populations have shown that NAFLD is an independent risk factor for CL, and CL is an independent risk factor for NAFLD. Insulin resistance is now being considered as a key link between NAFLD and the development of cholesterol cholelithiasis. In addition, changes in the expression of transcription factors, including hepatic X-receptor, farnesoid X-receptor, and membrane bile acid receptors, play an important role. It leads to increased lipogenesis in the liver and to bile cholesterol supersaturation, contributing to the development of gallstones and fatty liver. An equally important role in the pathogenesis of both diseases is played by gallbladder dysfunction, which serves as an important link between the liver and the intestine within the hepatic-gallbladder-intestinal axis and supports the metabolic homeostasis of cholesterol, triglycerides, and bile acids. It is supported by evidence that cholecystectomy increases the risk of NAFLD, contributes to insulin resistance, and promotes fat accumulation in the liver. The choice of drug therapy in patients with a combination of NAFLD and CL is based on knowledge of the general pathophysiological processes typical of both diseases. Drugs should comply with the principles of multipurpose monotherapy, targeting as many therapeutic targets as possible, and their combination should potentiate each other’s pharmacological effects. The treatment of patients with a combination of NAFLD and CL is primarily based on weight loss through exercise and a Mediterranean diet, enhanced by psyllium-containing agents and butyric acid, a key mediator of the Mediterranean diet’s positive effects. The drug of choice in patients with a combination of NAFLD and CL is ursodeoxycholic acid, exerting a pathogenetic effect on both diseases.
- Open Access
- 17 October 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 15,p. 42-47
Remote results of successful eradication Helicobacter pylori of patients with gastric ulcer (5-year follow-up)
Introduction . The Maastricht VI international guidelines define the most effective methods for diagnosing and treating H. pylori -associated peptic ulcer disease (PUD). Less attention has been paid to the subsequent course of PUD after successful eradication. Aim . To evaluate the impact of successful H. pylori eradication on the subsequent course of gastric ulcer disease (GUD). Materials and methods . Twenty patients with PUD after successful H. pylori eradication with a triple drug combination underwent annual EGDS for 5 years, including H. pylori biopsies, endoscopic pH monitoring, clinical dynamics, and blood gastrin and somatostatin levels. Results . Over a 5-year observation period, disease recurrences were detected: by clinical manifestations – in 50% of cases (in 83% of cases, relapses were low-symptom or asymptomatic), by EGDS – in 60% of cases (of which ulcers were recorded in 15% of cases and gastric erosions in 45%). Recurrence of H. pylori infection was recorded in 45% of patients (of which 15% – with gastric ulcers and 30% – with gastric erosions), and in 15% of patients, the cause of gastric erosions was the use of NSAIDs; it was accompanied by weak to moderate degrees of H. pylori contamination and gastrointestinal tract inflammation. Conclusion . A 5-year follow-up of PUD after successful eradication showed that H. pylori recurrence occurred in 45% of cases, with changes in the course of PUD. Benign (low-symptom and asymptomatic) recurrence was predominant, accompanied by mild to moderate H. pylori contamination and GM inflammation.
- 17 October 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 15,p. 42-47
Open AccessRemote results of successful eradication Helicobacter pylori of patients with gastric ulcer (5-year follow-up)
Introduction . The Maastricht VI international guidelines define the most effective methods for diagnosing and treating H. pylori -associated peptic ulcer disease (PUD). Less attention has been paid to the subsequent course of PUD after successful eradication. Aim . To evaluate the impact of successful H. pylori eradication on the subsequent course of gastric ulcer disease (GUD). Materials and methods . Twenty patients with PUD after successful H. pylori eradication with a triple drug combination underwent annual EGDS for 5 years, including H. pylori biopsies, endoscopic pH monitoring, clinical dynamics, and blood gastrin and somatostatin levels. Results . Over a 5-year observation period, disease recurrences were detected: by clinical manifestations – in 50% of cases (in 83% of cases, relapses were low-symptom or asymptomatic), by EGDS – in 60% of cases (of which ulcers were recorded in 15% of cases and gastric erosions in 45%). Recurrence of H. pylori infection was recorded in 45% of patients (of which 15% – with gastric ulcers and 30% – with gastric erosions), and in 15% of patients, the cause of gastric erosions was the use of NSAIDs; it was accompanied by weak to moderate degrees of H. pylori contamination and gastrointestinal tract inflammation. Conclusion . A 5-year follow-up of PUD after successful eradication showed that H. pylori recurrence occurred in 45% of cases, with changes in the course of PUD. Benign (low-symptom and asymptomatic) recurrence was predominant, accompanied by mild to moderate H. pylori contamination and GM inflammation.
- Open Access
- 28 December 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 23,p. 112-117
How to achieve a long-term remission in patients with chronic gastrointestinal diseases?
The article presents the main aspects of pharmacotherapy of patients with chronic gastrointestinal (GI) diseases. The overall goal of our research was to confirm the current paradigm, under which the remission of diseases is achieved by using pharmacotherapy and maintained with minimum doses of drugs. The achievement of this goal is considered on the example of gastroesophageal reflux disease (GERD). A total of 140 patients were randomly selected and divided into three groups: Group 1 (60 patients with acid-dependent variant (ADV) of the disease) received PPIs at medium therapeutic doses for 8 weeks. It took on average 4 weeks of treatment to relieve clinical symptoms and 8 weeks of treatment to reverse morpho-endoscopic lesions on the esophageal mucosa. During the 36-week follow-up period without maintenance therapy, 5 patients (8.3%) remained in remission, while 55 patients (91.7%) had clinical and morphological exacerbations. Group 2 (60 patients with acid-independent variant (AIV)) received rebamipide (Rebagit) at a daily dose of 300 mg for 8 weeks. It took on average 4 weeks to relieve clinical symptoms and 8 weeks to reverse morpho-endoscopic lesions on the esophageal mucosa. During the 48-week follow-up period without maintenance therapy, 6 patients (10%) remained in remission, while 90% of patients had exacerbations. Without pharmacological support, exacerbation was observed in the majority of patients (91.7%) within 48 weeks. Therefore, the prescription of maintenance therapy was required. In Group 3, 10 patients with ADV received omeprazole at a dose of 10 mg per day for 8 weeks after completing the main therapy course; 10 patients with AIV received rebamipide at a dose of 100 mg per day within the same period. During the long-term (48 weeks) follow-up period, the disease exacerbation was identified only in a third of patients with both ADV and AID GERD, and it only manifested as clinical symptoms of the disease without morpho-endoscopic lesions on the esophageal mucosa. Most patients remained in stable remission.
- 28 December 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 23,p. 112-117
Open AccessHow to achieve a long-term remission in patients with chronic gastrointestinal diseases?
The article presents the main aspects of pharmacotherapy of patients with chronic gastrointestinal (GI) diseases. The overall goal of our research was to confirm the current paradigm, under which the remission of diseases is achieved by using pharmacotherapy and maintained with minimum doses of drugs. The achievement of this goal is considered on the example of gastroesophageal reflux disease (GERD). A total of 140 patients were randomly selected and divided into three groups: Group 1 (60 patients with acid-dependent variant (ADV) of the disease) received PPIs at medium therapeutic doses for 8 weeks. It took on average 4 weeks of treatment to relieve clinical symptoms and 8 weeks of treatment to reverse morpho-endoscopic lesions on the esophageal mucosa. During the 36-week follow-up period without maintenance therapy, 5 patients (8.3%) remained in remission, while 55 patients (91.7%) had clinical and morphological exacerbations. Group 2 (60 patients with acid-independent variant (AIV)) received rebamipide (Rebagit) at a daily dose of 300 mg for 8 weeks. It took on average 4 weeks to relieve clinical symptoms and 8 weeks to reverse morpho-endoscopic lesions on the esophageal mucosa. During the 48-week follow-up period without maintenance therapy, 6 patients (10%) remained in remission, while 90% of patients had exacerbations. Without pharmacological support, exacerbation was observed in the majority of patients (91.7%) within 48 weeks. Therefore, the prescription of maintenance therapy was required. In Group 3, 10 patients with ADV received omeprazole at a dose of 10 mg per day for 8 weeks after completing the main therapy course; 10 patients with AIV received rebamipide at a dose of 100 mg per day within the same period. During the long-term (48 weeks) follow-up period, the disease exacerbation was identified only in a third of patients with both ADV and AID GERD, and it only manifested as clinical symptoms of the disease without morpho-endoscopic lesions on the esophageal mucosa. Most patients remained in stable remission.
- Open Access
- 16 October 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 15,p. 95-102
Gallstone disease: current pharmacotherapy options
Introduction. Gallstone disease is one of the most common diseases of the digestive system, its prevalence rate averaged to 10–15%, which is associated with high healthcare costs for patient management such as diagnosis, cholecystectomy with over 500 000 operations performed per year in the Russian Federation, and pharmacotherapy, which is increasingly used for the combined treatment.Aim. To assess the clinical efficacy and safety of hymecromon, a domestic drug, in patients with dyspeptic form of GSD.Materials and methods. A total of 30 patients (14 men and 16 women) with gallstones in their gallbladders were observed in the study. The patients were divided into 2 groups: Group 1 included 15 patients who received hymecromone at a dose of 600 mg/ day; Group 2 included 15 patients who received hymecromone at a dose of 1200 mg/day. The course of therapy was 21 days.Results. Intensity of all GSD symptoms significantly decreased by the end of hymecromone therapy in patients of both groups. Almost all patients reported a stool normalization. The use of hymecromone at a dose of 400 mg three times a day did not result in loose stools, and in patients who had loose stools before initiation of treatment, hymecromone contributed to the normalization of its frequency and nature. Vomiting, urge to retch and loss of appetite were completely discontinued in patients who received hymecromone at a dose of 1200 mg/day, however, there were no significant differences between Groups 1 and 2 in the changes in symptoms. No adverse events or side effects were observed during therapy.Conclusion. The therapy had a beneficial effect on upper gastrointestinal symptoms and bowel dysfunction (flatulence, diarrhoea, constipation). A significant improvement in the patients’ quality of life based on GSRS questionnaire scores was noted. The domestic drug Odecromon is considered to be effective in the treatment of dyspeptic GSD.
- 16 October 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 15,p. 95-102
Open AccessGallstone disease: current pharmacotherapy options
Introduction. Gallstone disease is one of the most common diseases of the digestive system, its prevalence rate averaged to 10–15%, which is associated with high healthcare costs for patient management such as diagnosis, cholecystectomy with over 500 000 operations performed per year in the Russian Federation, and pharmacotherapy, which is increasingly used for the combined treatment.Aim. To assess the clinical efficacy and safety of hymecromon, a domestic drug, in patients with dyspeptic form of GSD.Materials and methods. A total of 30 patients (14 men and 16 women) with gallstones in their gallbladders were observed in the study. The patients were divided into 2 groups: Group 1 included 15 patients who received hymecromone at a dose of 600 mg/ day; Group 2 included 15 patients who received hymecromone at a dose of 1200 mg/day. The course of therapy was 21 days.Results. Intensity of all GSD symptoms significantly decreased by the end of hymecromone therapy in patients of both groups. Almost all patients reported a stool normalization. The use of hymecromone at a dose of 400 mg three times a day did not result in loose stools, and in patients who had loose stools before initiation of treatment, hymecromone contributed to the normalization of its frequency and nature. Vomiting, urge to retch and loss of appetite were completely discontinued in patients who received hymecromone at a dose of 1200 mg/day, however, there were no significant differences between Groups 1 and 2 in the changes in symptoms. No adverse events or side effects were observed during therapy.Conclusion. The therapy had a beneficial effect on upper gastrointestinal symptoms and bowel dysfunction (flatulence, diarrhoea, constipation). A significant improvement in the patients’ quality of life based on GSRS questionnaire scores was noted. The domestic drug Odecromon is considered to be effective in the treatment of dyspeptic GSD.
- Open Access
- 15 October 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 15,p. 7-11
Irritable bowel syndrome: different approaches to therapy
This article provides present-date knowledge on irritable bowel syndrome (IBS) and different approaches to therapy. The method of presenting the materials is based on a specific clinical case, which includes the diagnostic algorithm, a list of modern medicines, defines pharmacological targets and, based on them, describes an approach to the selection of an adequate pharmaceutical drug. In the presented case, patient S. (37 years old) had a functional bowel disorder (stool disorder) for seven years, and short-term pharmacotherapy courses did not produce a lasting effect. The course of the disease had become more alarming over time. The medical examination confirmed irritable bowel syndrome (IBS) in the patient – a mixed variant with pain syndrome during exacerbations. The drug of choice was otilonium bromide, an intestinal antispasmodic, which differed from other intestinal antispasmodics in its complex mechanism of action and practically zero absorption (3%). It allowed for a long-term therapy reducing a risk of side effects. The duration of treatment was 15 weeks (40 mg 3 times a day), of which the last three weeks were regarded as the maintenance therapy at a dose of 40 mg once a day. Pain and dysbiosis were completely relieved at 4 weeks of treatment. Motility and stool were restored, which resulted in the improvement of the quality of life and the symptoms of anxiety were resolved almost completely after 12 weeks of treatment. Thus, otilonium bromide had an effect on all pharmacological targets that were established before treatment.
- 15 October 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 15,p. 7-11
Open AccessIrritable bowel syndrome: different approaches to therapy
This article provides present-date knowledge on irritable bowel syndrome (IBS) and different approaches to therapy. The method of presenting the materials is based on a specific clinical case, which includes the diagnostic algorithm, a list of modern medicines, defines pharmacological targets and, based on them, describes an approach to the selection of an adequate pharmaceutical drug. In the presented case, patient S. (37 years old) had a functional bowel disorder (stool disorder) for seven years, and short-term pharmacotherapy courses did not produce a lasting effect. The course of the disease had become more alarming over time. The medical examination confirmed irritable bowel syndrome (IBS) in the patient – a mixed variant with pain syndrome during exacerbations. The drug of choice was otilonium bromide, an intestinal antispasmodic, which differed from other intestinal antispasmodics in its complex mechanism of action and practically zero absorption (3%). It allowed for a long-term therapy reducing a risk of side effects. The duration of treatment was 15 weeks (40 mg 3 times a day), of which the last three weeks were regarded as the maintenance therapy at a dose of 40 mg once a day. Pain and dysbiosis were completely relieved at 4 weeks of treatment. Motility and stool were restored, which resulted in the improvement of the quality of life and the symptoms of anxiety were resolved almost completely after 12 weeks of treatment. Thus, otilonium bromide had an effect on all pharmacological targets that were established before treatment.